ANDOVER, Mass.--(BUSINESS WIRE)--Diomed Holdings, Inc. (AMEX: DIO - News), a leading developer and marketer of minimally invasive medical technologies, including its patented EVLT® laser treatment for varicose veins, today announced that it has received notice from the American Stock Exchange advising the Company that the AMEX has determined to seek to delist the Company’s common stock on the basis that the Company has not demonstrated a reasonable probability that the Company will regain compliance with Sections 1003(a)(ii) and (iii) of the AMEX Company Guide’s standards for continued listing on the Exchange. The standards require that a company maintain at least $4 million in stockholders’ equity if the company has sustained losses from continuing operations in three of its four most recent fiscal years and at least $6 million in stockholders’ equity if the company has sustained losses from continuing operations in its five most recent fiscal years.
